Pharmacokinetics of Oral Mirabegron With Different Release Rates Versus Intravenous (IV) Mirabegron

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Astellas Pharma Inc
ClinicalTrials.gov Identifier:
NCT00940121
First received: July 13, 2009
Last updated: July 1, 2013
Last verified: July 2013
  Purpose

The purpose of this study is to assess the pharmacokinetics of three doses of oral mirabegron formulations with three different release rates versus three doses of mirabegron administered intravenously; to study safety and side effects of the oral and IV doses of mirabegron.


Condition Intervention Phase
Healthy
Pharmacokinetics of Mirabegron
Drug: mirabegron
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Official Title: A Phase 1, Open-Label, Randomized, Parallel Dose Group Study to Assess the Pharmacokinetics of Mirabegron OCAS Formulations With Different Release Rates Versus IV Infusion in Healthy Volunteers

Resource links provided by NLM:


Further study details as provided by Astellas Pharma Inc:

Primary Outcome Measures:
  • Characterize the pharmacokinetic profile of 3 doses of oral mirabegron formulations with three different release rates vs. three doses of mirabegron administered intravenously [ Time Frame: 2 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Assess the safety and tolerability of three doses of orally administered mirabegron formulated with three different release rates [ Time Frame: 2 months ] [ Designated as safety issue: No ]
  • Assess the safety and tolerability of intravenously administered mirabegron [ Time Frame: 2 months ] [ Designated as safety issue: No ]

Enrollment: 91
Study Start Date: April 2009
Study Completion Date: July 2009
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1. mirabegron, low dose Drug: mirabegron
oral tablet
Other Name: YM178
Drug: mirabegron
IV solution
Other Name: YM178
Experimental: 2. mirabegron, middle dose Drug: mirabegron
oral tablet
Other Name: YM178
Drug: mirabegron
IV solution
Other Name: YM178
Experimental: 3. mirabegron, higher dose Drug: mirabegron
oral tablet
Other Name: YM178
Drug: mirabegron
IV solution
Other Name: YM178

Detailed Description:

Subjects will be randomly assigned to one of three oral mirabegron doses and then randomly assigned to one of three oral mirabegron doses and then randomly assigned to one of six treatment sequences.

For all subjects the first treatment will be a reference IV dose. Treatments 2, 3, and 4 will be a random order of slow, fast and target release oral doses of mirabegron. Treatment 5 will be a target release dose of mirabegron from a different batch.

There will be at least 10 day washout between dose administrations.

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • The subject must weigh at least 45 kg and have a body mass index (BMI) between 20.0 and 32.0 kg/m2
  • The subject must have a normal or clinically nonsignificant 12 lead ECG as well as normal or clinically non-significant laboratory test results
  • Female subjects must be post-menopausal (defined as at least 2 years without menses) surgically sterile, or practicing effective contraception, and will continue to use effective contraception during the study period. All females must be non-lactating, and should have a negative pregnancy test result
  • The subject must have negative test results for drugs of abuse and alcohol screens
  • The subject must have a good venous access in both arms

Exclusion Criteria:

  • The subject has evidence of QTc interval >430 msec for male, >450 msec for female
  • The subject has liver function test values (ALT, AST, or bilirubin) above the upper limit of normal
  • The subject has a history or presence of psychiatric illness, serious active or recurrent infection
  • The subject has a previous history of cancer other than basal cell carcinoma or Stage 1 squamous cell carcinoma that has not been in remission for at least 5 years
  • The subject has donated or lost ≥ 450 mL blood within 56 days prior to study drug administration or has donated plasma within 7 days prior to study drug administration
  • The subject has received or is anticipated to receive a prescription drug within 14 days (within 30 days for any long acting treatments such as depot formulations). Subject has taken any over-the-counter (OTC) medications, including complementary and alternative medicines (except for oral contraceptives and occasional use of acetaminophen of up to 2000 mg/day but not more than 4 days per week) within 14 days
  • The subject has consumed alcohol, xanthine derivative-containing beverages/food (tea/chocolate), grapefruit juice, grapefruit-containing products or Seville oranges (e.g., bitter marmalade) within 48 hours before admission into the unit
  • The subject has used tobacco-containing products and nicotine-containing products within 6 months
  • The subject consumes more than 5 units of alcoholic beverages (one unit is 12 ounces of beer, 4 ounces of wine or 1 ounce of spirits) per week, or has a history of substance abuse, drug addiction, or alcoholism within past 2 years
  • The subject is known to have hepatitis or HIV-1 and/or HIV-2, or is positive for hepatitis A antibody IgM, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00940121

Locations
United States, Washington
Tacoma, Washington, United States, 98418
Sponsors and Collaborators
Astellas Pharma Inc
Investigators
Study Director: Use Central Contact Astellas Pharma Global Development
  More Information

Additional Information:
Publications:
Responsible Party: Astellas Pharma Inc
ClinicalTrials.gov Identifier: NCT00940121     History of Changes
Other Study ID Numbers: 178-CL-076
Study First Received: July 13, 2009
Last Updated: July 1, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Astellas Pharma Inc:
Healthy volunteer subjects
pharmacokinetics
YM178
mirabegron
IV infusion
oral administration

ClinicalTrials.gov processed this record on April 17, 2014